Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe a way to increase the good bacteria in your gut.
Link to Butyrate, anyone following this protocol?
https://selfhacked.com/blog/butyrate-health-benefits/
Response from TGA
Please accept this automated response as an acknowledgement that your enquiry has been received by the Therapeutic Goods Administration (TGA). It will be dealt with as soon as possible.
Straight forward enquiries are usually dealt with in a few days. Enquiries requiring a more detailed response or input from a specialist will be responded to within 20 working days.
If you have not heard from us within this time frame please contact us on 1800 020 653.
AUTO-REPLY: Please do not reply to this message. It has been generated automatically.
Let you know how they respond. Would that be BIG news if confirmed?
Shares sold short, are we close to a Bear Trap?
https://www.investopedia.com/terms/b/beartrap.asp
It would make my heart happy.
Excellent George thanks for posting.
Or the market population explodes... I would take it in a heartbeat if it
were available, restores neural plasticity, helps with the aging process,
as a prophylactic.
Who wouldn't want to this drug?
On telling the story... Everyday I get a chance to meet and discuss with a wide range of people(driving Uber). I have researchers from OHSU, VC funders, Members of Boards and to a person everyone is excited about the story that I tell and thank me for sharing. As I relate the story of Anavex, it's so big, that one person offered up; "and next week World Peace" :) one day we will break through the media's bias on reporting about our company. I have faith.
Are referring to pre IPO MSFT? Cause it IPO'd March 13th 1986 for 21 per share. Don't believe it ever got that low as I bought at 69 in Jan 87.
Today is dissemination day for short interest, will they start their coverage? 1 pm Pacific. Flat 6.2m last report. Thanks Zena for the Nasdaq trader link
Yesterday I sent the prime minister a tweet asking if he was going to discuss Anavex. Never know when you plant a seed what will happen.
Services said to call back at 8:45, 10 min prior to conference for access.
Yes, I went to that link too, that's why I tried to confirm with Conference Services. Guess we will have to wait and see.
Conference services hosts the webcast, they have not been informed of a change to format, such as a cancelation.
FYI, just talked to Conference services, they said that the Anavex conference has not been cancelled on their end.
Thanks George your informational research is outstanding.
Oops are right I quickly scanned the article this morning.
I did notice metformin, haven't some folks mentioned that drug?
Interesting article in Nature
https://www.nature.com/articles/d41586-019-02638-w
The rejuvenation of the Thyroid, any thoughts on whether 2-73 could have a
similar affect?
Per the CC Dr Missling would not confirm or deny a timeline on completion of the 2b/3 trial. The date entered in the clinical trial is a requirement for the form , but is not necessarily an actual date. He implies that the trial could wrap up quicker than the listed date.
Thanks for the clarification: )
Australia end of Sept
Just wondering what you are talking about, it is in Amsterdam, Netherlands
next year, do you have the AAIC switched with something else?
You know Mav, we would like to thank you for posting about SRPT; and that they think they have an answer to Rett syndrome. A quick look into their solution, cost 1m per treatment, skips the exon51 gene, doesn't show any statistical significance makes me want to sit down and buy some. Or I can buy something that actually works, Blarcamesine, safe and effect showing multiple effects, on heart rate, breathing, seizures (in Rett). The Clinical findings that SRPT provided needed a push from the patient community because the therapy really doesn't work. Sorry to shoot down their dream, but Anavex has the best solution.
Rett Syndrome examples from Patent
Talking to a patent attorney, I asked about examples listed in applications, are they real life examples or are they made up? His response was that you could make up the examples, but if you commit fraud on an application, your whole patent would be void.
It is believed that therapeutic doses of A-2-73 increases lifespan and improves locomotor, respiratory, and cardiac function in children with Rett Syndrome.
EXAMPLE 1
Breathing Variability Reduction
A 6 year old female presenting with Rett syndrome is administered oral doses of A2-73 at 4 mg daily for 10 days. On presentation, her breathing is abnormal. Her mean breaths per minute is calculated to assess breathing variability. After 10 days of A2-73, administration the ? (breaths/minute) was significantly reduced (implying less variability).
EXAMPLE 2
Cardiac Pulse Rate
A 10 year old female presents with Rett syndrome. Her real time cardiac pulse rate is monitored. Prior to commencing therapy, her heart rate is 49 beats per minute with substantial variability. Following treatment with oral doses of A2-73 at 20 mg daily for 5 days, the variability is reduced while the average rate is increased to 75 beats per minutes.
EXAMPLE 3
Seizure Reduction
An 18 month old female presents with Rett syndrome. She experiences 6 to 10 seizures per day prior to commencing therapy. She begins treatment with oral doses of A2-73 at 2 mg daily. After 5 days of treatment, the number of daily seizures is reduced to 3 or fewer.
EXAMPLE 4
Eating and Choking
A 20 year-old female presents with Rett syndrome. She experiences feeding difficulties exhibiting as choking and poor food intake prior to commencing therapy. She begins treatment with oral doses of A2-73 at 40 mg every other day. After 60 days of treatment, the instances of choking are reduced and she exhibits a 10% weight gain.
EXAMPLE 5
Angelman—Sleep and Seizures
A 25 year-old male presents with Angelman syndrome. He experiences disturbed sleep and frequent seizures prior to commencing therapy. He begins treatment with oral doses of A2-73 at 30 mg/day. After 15 days of treatment, his sleep is markedly less disturbed and his instances of seizure are reduced by 50%.
EXAMPLE 6
Williams Syndrome—Weight Gain
A 2 year-old male presents with Williams syndrome. He exhibits a failure to thrive with low weight gain. He begins treatment with i.v. doses of A2-73 at 5 mg every other day. After 60 days of treatment, he exhibits a 10% weight gain.
EXAMPLE 7
Smith-Magenis Syndrome—Sleep
A 5 year-old male presents with Smith-Magenis syndrome. He experiences disturbed sleep. He begins treatment with oral doses of A2-73 at 10 mg/day. After 15 days of treatment, his sleep is markedly less disturbed.
EXAMPLE 8
Multiple Sclerosis
A 17 year-old male presents with multiple sclerosis. He begins treatment with oral doses of A2-73 at 40 mg every fifth day. The total number of gadolinium-enhanced lesions on MRI at weeks 12, 16, 20 and 24 is substantially reduced as compared to his 12 week pretreatment MRI.
EXAMPLE 9
Multiple Sclerosis
A 27 year-old female presents with relapsing-remitting multiple sclerosis. She begins treatment with oral doses of A2-73 at 30 mg every other day for 3 months. She exhibits a significantly lower number of total gadolinium-enhancing lesions on monthly brain MRI up to month 6.
The pharmaceutical compositions provided herein can be administered chronically (“chronic administration”). Chronic administration refers to administration of a compound or pharmaceutical composition thereof over an extended period of time, e.g., for example, over 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or may be continued indefinitely, for example, for the rest of the subject's life. In certain embodiments, the chronic administration is intended to provide a constant level of the compound in the blood, e.g., within the therapeutic window over the extended period of time.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US236451262&tab=PCTDESCRIPTION
Anavex Now let's file the NDA/BLA
Would it be the metabolite of 2-73?
Ah thanks for the clarification
Thanks Kevli33, I noticed that the project's funding lists Genetec as the source. That would mean Roche would be in the mix. Makes me wonder about the new facility being built in Oregon I talked to three engineers last week checking on the site, I asked if they planned to manufacture monoclonal antibodies and they said no it was a finished product site. The plot thickens.
Lack of baseline data on gut bio. That was my thought too. Thinking out loud, maybe there is historical data to compare. Did they site any prior studies?
Agreed, containment of disease. Wouldn't you think that with containment the possibility of neural development (in Rett) has the possibility to continue on a more normalized path? Reversing pathology, if not too much damage has occurred in the underlying structures.
Good morning board---I was wondering if Cystic fibrosis could be a possible candidate for Anavex treatment?
It seems to be in our wheelhouse, a genetic mutation, with over 1500 mutations...
The CFTR protein is a channel protein that controls the flow of H2O and Cl- ions in and out of cells inside the lungs. When the CFTR protein is working correctly, ions freely flow in and out of the cells. However, when the CFTR protein is malfunctioning, these ions cannot flow out of the cell due to a blocked channel. This causes cystic fibrosis, characterized by the buildup of thick mucus in the lungs.
What say you?